Business
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
NEW HAVEN, Conn., August 07, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent company developments.
About this update from Recursion Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":244,"url":"https://media.zenfs.com/en/business-wire.com/b31cd709309676072c8168cc951c83e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W.eHKhYoVMLiPLC0KZskAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b31cd709309676072c8168cc951c83e8","width":480,"height":244}},"lazy":false},{"type":"text","content":"– Data Readouts from Cohort 1 and Cohort 2 of RLYB116 Confirmatory PK/PD Study on Track for 3Q and 4Q 2025, Respectively –","length":122,"tagName":"p","attribs":{}},{"type":"text","content":"– Sold Interest in REV102 to Recursion Pharmaceuticals for Up to $25 Million, including an Upfront Equity Payment of $7.5 Million –","length":131,"tagName":"p","attribs":{}},{"type":"text","content":"– Cash Runway into Mid-2027 –","length":29,"tagName":"p","attribs":{}},{"type":"text","content":"NEW HAVEN, Conn., August 07, 2025--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent company developments.","length":366,"tagName":"p"},{"type":"text","content":""The second quarter marked a pivotal step forward as we advanced our lead program, RLYB116, into a confirmatory PK/PD study, which is an important milestone that reflects the strength of our science and the dedication of our team. Meanwhile, the strategic divestiture of a preclinical asset underscores our commitment to disciplined portfolio management, enabling us to sharpen our focus and strengthen the balance sheet as we continue to develop transformative therapies for patients and build long-term value for shareholders," said Stephen Uden, M.D., Chief Executive Officer of Rallybio. "With the RLYB116 confirmatory PK/PD study underway, we continue to look forward to the release of topline data from Cohort 1 and Cohort 2, expected in the third and fourth quarter of 2025, respectively."","length":816,"tagName":"p"},{"type":"text","content":"Recent Business Highlights and Upcoming Milestones:","length":51,"tagName":"p"},{"...